January 18, 2023
(Alexandria, Virginia) — Today Consumer Action for a Strong Economy (CASE) sent a letter to high-level administrators at the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) alerting them to false claims made by Revance Therapeutics, Inc. regarding the efficacy of their injectable nueromodulator DAXXIFY.
At issue are claims by Revance that DAXXIFY benefits last 50 percent longer than extensive FDA testing of the product concluded, a figure that will mislead consumers and healthcare providers regarding the effectiveness and benefits of DAXXIFY. Calling for the agencies to take action, CASE chairman Gerard Scimeca noted, “The FDA has a unique and lifesaving duty to regulate and approve drugs and therapeutics that will improve the public health of our country, but they also must take action to enforce that their approved
labels are used correctly. Patients and physicians across the United States are injecting DAXXIFY without accurate information – that is a dangerous precedent to set.”
The full text of the letter can be read here.
